Moyamoya Disease vs. Syndrome: What Are the Differences?

Moyamoya disease and moyamoya syndrome produce the same hallmark finding on brain imaging: progressive narrowing of major arteries at the base of the brain, accompanied by a tangle of tiny compensatory blood vessels that look, on an angiogram, like a puff of smoke (moyamoya in Japanese). The critical difference is cause. Moyamoya disease is idiopathic, meaning no underlying condition explains why the arteries are narrowing. Moyamoya syndrome is the same arterial pattern occurring in someone who has a recognized associated condition, such as sickle cell disease, neurofibromatosis, or prior radiation to the head.¹ That distinction sounds neat on paper, but in practice it gets complicated fast.

Why the Distinction Matters

The difference is not just a labeling exercise. In moyamoya disease, the arterial narrowing is the primary problem, driven by factors that are still not fully understood but appear to be heavily genetic. In moyamoya syndrome, the narrowing is secondary to something else happening in the body, and treating or managing that underlying condition can sometimes influence the vascular picture. A child with sickle cell disease who develops moyamoya-pattern vessels, for instance, may benefit from disease-modifying therapies for sickle cell alongside any vascular interventions. Someone whose moyamoya pattern appeared after cranial radiation has a known trigger that a purely idiopathic patient does not.

The diagnostic process reflects this. When doctors see the classic angiographic findings, they look for known associated conditions. If none are found, and the stenosis fits the characteristic pattern of the internal carotid arteries and their proximal branches, the diagnosis is moyamoya disease. If a recognized associated disorder or vascular risk factor is present, it is classified as moyamoya syndrome.² The imaging itself can look identical in both cases.

The Genetic Side of the Disease Form

Moyamoya disease has a strong genetic component, particularly in East Asian populations. The most important genetic discovery has been a variant in the RNF213 gene, located on chromosome 17. A specific change in this gene, known as R4810K, is the strongest known genetic risk factor for moyamoya disease in Japanese, Korean, and Chinese populations.³ The risk associated with carrying this variant is remarkably high: one study estimated the odds ratio at over 50 among Asian populations tested, and the variant’s contribution to disease in the Japanese and Korean populations was estimated at roughly half to two-thirds of all cases.⁴ This variant, however, was not detected in the Caucasian samples studied, which helps explain why moyamoya disease is far more common in East Asia than elsewhere.

Having the gene variant alone does not guarantee someone will develop the disease. Research suggests that inflammatory signals and environmental factors interact with the genetic susceptibility. Laboratory work has shown that the RNF213 protein is activated by inflammatory signaling and affects how blood vessels grow. In mice engineered to carry the equivalent of the human R4810K variant, the brain’s ability to sprout new blood vessels under low-oxygen conditions was suppressed, but only in specific cell types.⁵ This points to a model where genetic predisposition meets some kind of inflammatory or environmental trigger to set off the cascade of arterial narrowing.

Conditions That Cause Moyamoya Syndrome

A wide range of conditions have been linked to moyamoya syndrome. Some of the most commonly recognized include neurofibromatosis type 1, Down syndrome, sickle cell disease, thyroid disease, and prior cranial radiation.⁶ Each of these has a different mechanism by which it may promote the arterial changes, and the strength of the associations varies.

Sickle cell disease is one of the more studied triggers. The abnormal red blood cells in sickle cell disease set off chronic inflammation in blood vessel walls, causing the inner lining to thicken and progressively narrow the major arteries of the brain’s base.⁷ The collateral vessels that form in response are the same moyamoya pattern seen in the idiopathic disease form.⁸

Neurofibromatosis type 1 (NF1) is another well-established association. One reason the link is particularly interesting genetically is that the NF1 gene sits on chromosome 17 as well, fairly close to the RNF213 gene implicated in moyamoya disease, which has led researchers to speculate that the proximity of these two genetic regions may not be coincidental.⁹

Cranial radiation, especially in children treated for brain tumors, is a recognized trigger. A study of children who received radiation for primary brain tumors found that about 3.5% developed moyamoya syndrome afterward. The risk was highest in children whose tumors were located near the circle of Willis (the ring of arteries at the brain’s base) and in those who received higher radiation doses to that area. Children who also had neurofibromatosis type 1 faced compounded risk.¹⁰

How Symptoms Show Up

Regardless of whether the underlying condition is classified as disease or syndrome, the symptoms stem from the same problem: not enough blood reaching parts of the brain, or bleeding from the fragile collateral vessels that have formed to compensate. What those symptoms look like depends heavily on age.

In children, the predominant presentation is ischemic: transient ischemic attacks and strokes caused by insufficient blood flow. Cognitive decline, seizures, and involuntary movements are also more common in younger patients. Adults, by contrast, are more likely to present with bleeding inside the brain. There are two peaks of incidence, one around age 10 and another between 30 and 40, and the adult peak appears to occur later in women than in men.¹¹

Cognitive difficulties deserve special attention because they can be subtle and are easily overlooked. In adults with moyamoya disease, problems with executive function are the most common cognitive issue, affecting over half of patients in one long-term study. Difficulties with processing speed, visual memory, and performance IQ were also frequent. These deficits tended to stay stable over time rather than dramatically worsening, but they also did not improve.¹² Even more striking, cognitive impairment has been documented in patients who have not yet had a stroke or other obvious clinical event, suggesting that chronic low blood flow to the brain can quietly erode cognitive function before any dramatic symptoms appear.¹³

Children with moyamoya disease face quality-of-life challenges that go beyond what their physical symptoms might suggest. Even children who have not had a stroke report lower quality of life than healthy peers, comparable to children with chronic illnesses. Researchers have recommended that mental health support be part of routine care for these children, not just an afterthought when something goes visibly wrong.¹⁴

Imaging and Diagnosis

The classic diagnostic tool is cerebral angiography, which directly visualizes the narrowed arteries and the cloud of tiny moyamoya collaterals. Magnetic resonance angiography can also show the pattern and is less invasive. The Suzuki grading system has traditionally been used to stage the severity of the disease based on how the angiographic picture progresses. Interestingly, though, the Suzuki stage at diagnosis does not reliably predict what symptoms a patient will have, how they will do after surgery, or even what their brain scans will show in terms of existing damage (apart from injury to the deep brain structures).¹⁵ This is a good example of how the structural picture and the clinical picture do not always move in lockstep.

Newer imaging approaches are focusing on measuring actual blood flow in the brain rather than just looking at anatomy. Arterial spin labeling (ASL), a type of MRI technique that does not require injected contrast dye, can measure cerebral blood flow and has been shown to effectively replace older contrast-based perfusion imaging for moyamoya patients.¹⁶ More advanced versions of ASL that measure blood flow at multiple time points can improve accuracy and may serve as a useful marker for tracking the disease over time.¹⁷ After surgical treatment, combining different ASL approaches has outperformed using a single technique alone for judging how well blood flow has been restored.¹⁸

Treatment Approaches for Both Forms

There is no cure for either moyamoya disease or moyamoya syndrome. No medication can reverse the arterial narrowing. Treatment focuses on preventing strokes and managing symptoms, and the strategies are broadly similar regardless of whether the patient has disease or syndrome, though managing the underlying condition in syndrome cases adds a layer of complexity.¹⁹

Surgical revascularization is the main intervention for patients who are symptomatic. The goal is to create new pathways for blood to reach the brain, bypassing the narrowed arteries. There are three basic approaches: direct bypass (physically connecting a scalp artery to a brain artery), indirect bypass (placing blood-vessel-rich tissue against the brain surface and letting new vessels grow in over weeks to months), and combined procedures that use elements of both. A large meta-analysis found that direct and combined bypasses produced better long-term outcomes than indirect bypass alone in adults, with lower rates of late stroke and late brain bleeding. However, indirect bypass had a lower risk of bleeding in the period right after surgery.²⁰ For children, indirect procedures are often preferred because direct microsurgical connections to small pediatric vessels are technically harder, and children tend to grow robust collateral networks from indirect procedures on their own.

On the medical side, antiplatelet medications like aspirin are commonly used, particularly in the United States. The evidence for their benefit, however, is mixed. A systematic review found that antiplatelet therapy was associated with a reduced risk of brain bleeding in moyamoya patients but did not clearly reduce ischemic strokes or improve overall independence.²¹ A separate systematic review similarly concluded that antiplatelet treatment did not demonstrate a clear protective effect against ischemic strokes, but it did not appear to increase bleeding risk either.²² This is one of those areas where the evidence is thin enough that practice patterns vary from center to center. Some patients with asymptomatic moyamoya disease are simply watched with regular imaging rather than started on any medication. A recent study found that even in these asymptomatic patients, the annual risk of having a stroke was about 1% per affected hemisphere, which is low enough that some doctors question the value of medication but high enough that nobody is comfortable ignoring it entirely.¹⁹

Monitoring for Progression

Moyamoya disease is progressive. Even patients who are asymptomatic at diagnosis or who initially have disease on only one side of the brain can develop worsening narrowing or bilateral involvement over time. Follow-up research has emphasized that careful ongoing monitoring is essential for all patients, including those who seem clinically stable, to catch progression before it leads to a stroke.²³ This is true for both disease and syndrome, though the pace of progression may be influenced by the underlying condition in syndrome cases.

Circulating Biomarkers and Future Diagnostics

One area of active research is the search for blood-based markers that could help diagnose or track moyamoya without repeated imaging. Patients with moyamoya disease have been found to have significantly higher levels of circulating endothelial progenitor cells (a type of cell involved in forming new blood vessels) compared to both healthy people and people with atherosclerotic cerebrovascular disease.²⁴ Similar findings have been reported in children with moyamoya, along with elevated levels of proteins involved in blood vessel growth found in their cerebrospinal fluid.²⁵ These findings make biological sense: the body is trying to compensate for restricted blood flow by ramping up vessel-formation signals. Whether any of these markers will prove useful in clinical practice for early diagnosis or for predicting who will progress remains to be seen, but they offer a window into what is happening at the molecular level.

Pregnancy in Women with Moyamoya

Pregnancy is a particular concern because it stresses the cardiovascular system in ways that could tip a fragile cerebral blood supply toward crisis. A systematic review found that women with moyamoya disease who were diagnosed before pregnancy generally did well, especially if they had already undergone bypass surgery: about 95% had good outcomes, and no adverse fetal outcomes were reported in that group. About two-thirds of these women delivered by cesarean section.²⁶

The picture was more concerning for women first diagnosed with moyamoya because of a stroke during pregnancy. In that group, symptoms typically appeared around 29 weeks of gestation, roughly 70% presented with brain bleeding rather than clot-related strokes, maternal mortality was about 14%, and fetal loss approached a quarter of cases. The consensus from the evidence is that moyamoya is not a reason to avoid pregnancy, but maintaining stable blood pressure and proper ventilation during labor and delivery is critical. The method of delivery (cesarean versus vaginal) matters less than keeping hemodynamics steady throughout.²⁷

When the Line Between Disease and Syndrome Gets Blurry

The clean separation between moyamoya disease and syndrome is useful for organizing clinical thinking, but it can be somewhat artificial. Consider a patient with the RNF213 R4810K variant who also has thyroid disease. Is the arterial narrowing caused by the genetic variant (making it disease) or triggered by the thyroid condition (making it syndrome)? In practice, both may be contributing. The same genetic variant identified as the primary driver of moyamoya disease has been described as part of a broader spectrum of vascular problems, sometimes called RNF213 vasculopathy, that does not fit neatly into either category.³

Some researchers have argued that moyamoya syndrome should be thought of as a window into moyamoya disease itself, suggesting that the associated conditions may be acting as triggers or accelerants in people who already have some underlying vascular susceptibility.⁶ Under this view, the difference between disease and syndrome is less about two fundamentally different conditions and more about where on a spectrum a given patient falls, with purely genetic cases at one end and environmentally triggered cases at the other. The clinical reality is that the distinction still guides workup and management: syndrome patients need their underlying condition addressed, and the presence of an associated disorder may change the approach to anticoagulation, anesthesia, or follow-up. But the boundary between the two is less sharp than the terminology implies.